CCR2 (a receptor for CCL2) and CCR5 (a receptor for CCL3 and CCL4) have been proposed to be targets for antifibrotic therapy due to their ability to promote liver fibrosis and macrophage infiltration20,45. The gene discussed is CCR5; the disease is Hepatic fibrosis.